Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

MLA

Percival, Mary-Elizabeth M., et al. “Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.” JCO Oncology Practice, vol. 16, no. 9, Sept. 2020, pp. 571–78. EBSCOhost, https://doi.org/10.1200/OP.20.00241.

APA

Percival, M.-E. M., Lynch, R. C., Halpern, A. B., Shadman, M., Cassaday, R. D., Ujjani, C., Shustov, A., Tseng, Y. D., Liu, C., Pergam, S., Libby, E. N., Scott, B. L., Smith, S. D., Green, D. J., Gopal, A. K., & Cowan, A. J. (2020). Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. JCO Oncology Practice, 16(9), 571–578. https://doi.org/10.1200/OP.20.00241

Chicago

Percival, Mary-Elizabeth M, Ryan C Lynch, Anna B Halpern, Mazyar Shadman, Ryan D Cassaday, Chaitra Ujjani, Andrei Shustov, et al. 2020. “Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.” JCO Oncology Practice 16 (9): 571–78. doi:10.1200/OP.20.00241.